Skip to main content

REVIEW article

Front. Immunol.
Sec. Inflammation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1494250
This article is part of the Research Topic Immunological Aspects of Fibrosis Pathogenesis: Novel Mechanisms and Therapeutic Strategies View all 8 articles

The Role of Macrophages in Liver Fibrosis: Composition, Heterogeneity, and Therapeutic Strategies

Provisionally accepted
Xiaocao Ma Xiaocao Ma 1,2Jia Qiu Jia Qiu 3,4Shubiao Zou Shubiao Zou 1Liling Tan Liling Tan 1Tingting Miao Tingting Miao 1*
  • 1 Department of Nuclear Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 2 Department of Clinical Laboratory, Jiangxi Province Key Laboratory of Laboratory Medicine, Nanchang, China
  • 3 Department of Radiology, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi Province, China
  • 4 Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China

The final, formatted version of the article will be published soon.

    Macrophages, the predominant immune cells in the liver, are essential for maintaining hepatic homeostasis and responding to liver injury caused by external stressors. The hepatic macrophage population is highly heterogeneous and plastic, mainly comprised of hepatic resident kuffer cells (KCs), monocyte-derived macrophages (MoMφs), lipid-associated macrophages (LAMs), and liver capsular macrophages (LCMs). KCs, a population of resident macrophages, are localized in the liver and can self-renew through in situ proliferation. However, MoMφs in the liver are recruited from the periphery circulation to the liver. LAMs are a self-renewing subgroup of liver macrophages near the bile duct. While LCMs are located in the liver capsule and are derived from peripheral monocytes. LAMs and LCMs are also involved in liver damage induced by various factors. Hepatic macrophages exhibit distinct phenotypes and functions depending on the specific microenvironment in the liver. KCs are critical for initiating inflammatory responses after sensing tissue damage, while the MoMφs infiltrated in the liver are implicated in both the progression and resolution of chronic hepatic inflammation and fibrosis. The regulatory function of liver macrophages in hepatic fibrosis has attracted significant interest in current research. Numerous literatures have documented that the MoMφs in the liver have a dual impact on the progression and resolution of liver fibrosis. The MoMφs in the liver can be categorized into two subtypes based on their Ly-6C expression level: inflammatory macrophages with high Ly-6C expression (referred to as Ly-6C hi subgroup macrophages) and reparative macrophages with low Ly-6C expression (referred to as Ly-6C lo subgroup macrophages). Ly-6C hi subgroup macrophages are conducive to the occurrence and progression of liver fibrosis, while Ly-6C lo subgroup macrophages are associated with the degradation of extracellular matrix (ECM) and regression of liver fibrosis. Given this, liver macrophages play a pivotal role in the occurrence, progression, and regression of liver fibrosis. Based on these studies, treatment therapies targeting liver macrophages are also being studied gradually. This review aims to summarize researches on the composition and origin of liver macrophages, the macrophage heterogeneity in the progression and regression of liver fibrosis, and anti-fibrosis therapeutic strategies targeting macrophages in the liver.

    Keywords: liver fibrosis, ECM, macrophage, heterogeneity, therapeutic strategies

    Received: 10 Sep 2024; Accepted: 31 Oct 2024.

    Copyright: © 2024 Ma, Qiu, Zou, Tan and Miao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tingting Miao, Department of Nuclear Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.